SEC Form 4 · accession 0001179110-19-001574
Theravance Biopharma, Inc. · TBPH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Philip D Worboys
Officer — SVP, Translational Science
Period of report
Feb 5, 2019
Accepted (ET)
Feb 7, 2019 · 5:51 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001583107
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary Shares | Feb 5, 2019 | A | 65,000 | $0.00 | A | 227,380 | D | |
| Ordinary SharesF1 | Feb 5, 2019 | A | 47,250 | $0.00 | A | 274,630 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1On March 15, 2016, the reporting person was granted a performance stock award that vests based on the achievement of certain performance conditions over a five-year timeframe from 2016 through December 31, 2020 and continued employment. On February 5, 2019, the performance conditions applicable to 47,250 shares were achieved and such shares will vest on February 20, 2020, subject to the reporting person's continued service.